Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Philip Lane

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Science (New York, N.Y.)|August 10, 2019
How to lose tumor suppressionDavid Philip Lane
Cold Spring Harbor Perspectives in Medicine|February 15, 2017
Exploiting the p53 Pathway for TherapyChit Fang Cheok, David Philip Lane
Oncotarget|March 25, 2014
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemiaBan Xiong Tan, Kian Hoe Khoo, Tit Meng Lim, et al.
NPJ Breast Cancer|July 20, 2017
A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2Wai-Heng Lua, Samuel Ken-En Gan, David Philip Lane, et al.
Frontiers in Oncology|October 17, 2019
The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer CellsAnja Charlotte Lundgren Mortensen, Diana Spiegelberg, Christopher John Brown, et al.
Journal of Immunological Methods|November 5, 2019
The quantification of antibody elements and receptors subunit expression using qPCR: The design of VH, VL, CH, CL, FcR subunits primers for a more holistic view of the immune systemWei-Li Ling, Yuen-Ling Ng, Anil Wipat, et al.
Frontiers in Immunology|March 30, 2018
Effect of VH-VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA BindingWei-Li Ling, Wai-Heng Lua, Jun-Jie Poh, et al.
Scientific Reports|January 17, 2018
The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-bindingWai-Heng Lua, Wei-Li Ling, Joshua Yi Yeo, et al.
Scientific Reports|July 19, 2018
Author Correction: The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-bindingWai-Heng Lua, Wei-Li Ling, Joshua Yi Yeo, et al.
Frontiers in Oncology|October 5, 2020
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer ModelDiana Spiegelberg, Anja Charlotte Lundgren Mortensen, Kartika Dyah Palupi, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Science (New York, N.Y.)|August 10, 2019
How to lose tumor suppressionDavid Philip Lane
Cold Spring Harbor Perspectives in Medicine|February 15, 2017
Exploiting the p53 Pathway for TherapyChit Fang Cheok, David Philip Lane
Oncotarget|March 25, 2014
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemiaBan Xiong Tan, Kian Hoe Khoo, Tit Meng Lim, et al.
NPJ Breast Cancer|July 20, 2017
A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2Wai-Heng Lua, Samuel Ken-En Gan, David Philip Lane, et al.
Frontiers in Oncology|October 17, 2019
The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer CellsAnja Charlotte Lundgren Mortensen, Diana Spiegelberg, Christopher John Brown, et al.
Journal of Immunological Methods|November 5, 2019
The quantification of antibody elements and receptors subunit expression using qPCR: The design of VH, VL, CH, CL, FcR subunits primers for a more holistic view of the immune systemWei-Li Ling, Yuen-Ling Ng, Anil Wipat, et al.
Frontiers in Immunology|March 30, 2018
Effect of VH-VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA BindingWei-Li Ling, Wai-Heng Lua, Jun-Jie Poh, et al.
Scientific Reports|January 17, 2018
The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-bindingWai-Heng Lua, Wei-Li Ling, Joshua Yi Yeo, et al.
Scientific Reports|July 19, 2018
Author Correction: The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-bindingWai-Heng Lua, Wei-Li Ling, Joshua Yi Yeo, et al.
Frontiers in Oncology|October 5, 2020
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer ModelDiana Spiegelberg, Anja Charlotte Lundgren Mortensen, Kartika Dyah Palupi, et al.
Pageof 2